FIXX

Homology Medicines Inc (FIXX) | Rumor.io

Homology Medicines

FIXX

Attention (50-day avg)0%

Attention rank (50-day avg)#4,144

Bullish sentiment (50-day avg)—

Price to earnings ratio-4.73

Market capitalization42.1M

Earnings per share-1.95

Dividend yield (TTM)—

Revenue (annual)1.2M

Net income (annual)-113M

Social

What share of all stock conversation is about FIXX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Nov 16

FIXX has been significantly impacted by a merger deal, with the stock down 34.08% and trading at a market cap of $27 million.
The deal has left FIXX with a valuation of $17 million, implying a $68 million valuation for the new company, which has $115 million in cash.
Some analysts believe FIXX has a liquidation value of over $1 billion, excluding the OXB equity stake and any value of IP, making the current price a potential buy opportunity.

Generated by AI

Sentiment

Of the messages about FIXX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	—
Bearish	—	—	—	—

Topics

Of the messages about FIXX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	100%
Analysts	—	—	0%	0%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0%

Announcements· Jul 28

Homology Medicines, Inc. ($FIXX) reduced its workforce by approximately 80 employees and made $6.3M in severance payments.
The company has announced a plan to evaluate strategic options, including a potential sale, and has halted development of its genetic medicines programs.
Homology Medicines' stock surged 27% premarket after the announcement, with the company's market value estimated to be around $120M, including $120M in cash and a 20% equity stake in Oxford Biomedica Sol.

Controversies· Apr 9

Investors in Homology Medicines, Inc. (FIXX) may be eligible to lead a class action lawsuit due to substantial losses.
A video explanation of FIXX stock highlights the company's significant losses.
FIXX investors have expressed hope for the stock's price to increase.

Generated by AI

Community

Of the messages about FIXX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	0%
Newcomers	—	—	100%	100%

Regulars· Feb 22

$FIXX has been placed on clinical hold for its lead program, according to an email sent by the company after market close on Friday.
Analysts at RBC, Oppenheimer, and Chardan Capital have lowered their price targets for $FIXX to $4, $9, and $15, respectively, due to safety concerns and reduced efficacy expectations.
Homology Medicines ($FIXX) has been downgraded to a "Perform" rating by RBC and a "Neutral" rating by BTIG, with some analysts maintaining a "Buy" rating despite lowered price targets.

Newcomers· Nov 16

The market is highly critical of the merger deal between FIXX and Q32 Bio, with many users expressing anger and disappointment at the deal's impact on shareholders.
The valuation of FIXX's assets is being questioned, with some users suggesting that the company's net cash position is much lower than previously assumed, and that the deal's valuation is overly optimistic.
The insider ownership and compensation of FIXX's executives are being highlighted as a potential red flag, with some users suggesting that the executives' interests may not be aligned with those of shareholders.

Generated by AI

Targeted topical therapies, phototherapy optimization, artificial intelligence and expanding specialist care are accelerating the transition toward evidence-based, patient-centered vitiligo treatment. Vitiligo Therapeutics Market Vitiligo Therapeutics Market Dublin, July 17, 2026 (GLOBE NEWSWIRE) -- The "Vitiligo Therapeutics Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.The global vitiligo therapeutics market is projected to reach USD 1.72 billion in 20

2mo agoYahoo Finance

Also Discussed

Investors talking about FIXX also mention

#	Name	Attention
1	AVRO - AVROBIO, Inc.	——
2	ImageneBio, Inc.IKNA	0%0
3	GRPH - Graphite Bio, Inc.	——
4	Fennec Pharmaceuticals Inc.FENC	0%0
5	Cabaletta Bio Inc.CABA	0%0
6	Editas Medicine, Inc.EDIT	0%+0
7	Syros Pharmaceuticals Inc.SYRS	0%0
8	SYBX - Synlogic, Inc.	——
9	Solid Biosciences Inc.SLDB	0.3%new
10	ORTX - Orchard Therapeutics plc	——